• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Quick Take: Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide

byDonna LeetandAliya Ramjaun
December 13, 2018
in Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Percutaneous radiofrequency ablation effective in small, exophytic renal cell carcinoma [Classics Series]

CT scans increase the risk of malignancy in children and young adults [Classics Series]

Magnetic resonance cholangiopancreatography diagnoses bile duct obstruction with high sensitivity and specificity [Classics Series]

Umbilical cord blood (UCB) is a rich source of stem cells for transplantation in patients with hematologic malignancies. However, its widespread utilization has been limited by the generally slow rate of hematopoietic recovery. In a first-in-human pilot study of an ex-vivo expanded UCB product (NiCord) used in combination with nicotinamide to expand repopulating hematopoietic stem cells, stable NiCord-derived hematopoiesis was observed for more than 7 years. In this multicenter phase I/II single-arm study, 36 patients with high-risk hematologic malignancies and no readily available matched adult donor were transplanted with a single, expanded UCB graft (NiCord) after myeloablative conditioning. The primary outcomes were the incidence of neutrophil engraftment at 42 days and the incidence of secondary graft failure. Results were compared to data from a matched cohort of 146 patients who underwent UCB transplantation between 2010 and 2013 from the Center for International Blood and Marrow Transplant Research (CIBMTR). Researchers found that the age-adjusted cumulative incidence of neutrophil engraftment at 42 days after transplantation was higher in the NiCord recipients (94%) than in the CIBTMR comparator cohort (85%) (p<0.001). One NiCord recipient experienced primary graft failure, and two patients experienced secondary graft failure. The cumulative incidence of grade 2 to 4 graft-versus-host disease (GVHD) at day 100 was 44% in the NiCord recipients (95% CI 28% to 60%), and the cumulative incidence of chronic GVHD at 3 years was 40% (95% CI 24% to 57%). Overall, this study suggests that use of a stand-alone ex-vivo expanded UCB graft may be efficacious and safe. An ongoing phase III trial comparing NiCord to standard myeloablative UCB transplantation will provide conclusive results.

Click to read the study in JCO

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Hematopoietic stem-cell transplantationmalignancyNiCordstem cell
Previous Post

Radical prostatectomy significantly improves survival in localized prostate cancer: the SPCG-4 trial

Next Post

Study examines post-discharge pediatric mortality rate in Mozambique

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Neurology Classics

Percutaneous radiofrequency ablation effective in small, exophytic renal cell carcinoma [Classics Series]

August 19, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

CT scans increase the risk of malignancy in children and young adults [Classics Series]

August 15, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Magnetic resonance cholangiopancreatography diagnoses bile duct obstruction with high sensitivity and specificity [Classics Series]

August 4, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Breast ultrasound sensitive for cancer and carries a low false positive rate [Classics Series]

August 3, 2022
Next Post

Study examines post-discharge pediatric mortality rate in Mozambique

Intensive rehabilitation not superior to traditional therapy for arm function after stroke

Quick Take: Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

MitraClip does not significantly improve outcomes in secondary mitral regurgitation: the MITRA-FR trial

MitraClip does not significantly improve outcomes in secondary mitral regurgitation: the MITRA-FR trial

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options